
AUSTRALIA: Using plant-based active ingredients, Haleon’s PanaNatra tablets and soft capsules — now available in Australia – have been created to ease and manage mild muscle, joint and general pain. The line-up has three options, featuring patented ingredients to elevate the brand’s scientific credentials:
- PanaNatra Joint Pain Relief, formulated with Curcumin C3 Complex (a patented curcumin combination), Apresflex (a blend of boswellia extract enriched with boswellia oil & boswellic acid) and Bioperine (a unique blend of piperine that boosts absorption of curcumin)
- PanaNatra Muscle Pain Relief with Rhuleave-K, a combination of curcuminoids and boswellia
- PanaNatra Sleep & Pain Relief (Ashwagandha KSM-66)
Nicholas Hall Writes: My colleague Fiona Cooper, a staff writer at Insight Asia-Pacific, reminds me that investment in naturals was listed as part of Haleon’s growth strategy in its spin-off prospectus in mid-2022. While still in its early days as an independent company, as well as being the leading player in consumer health, Haleon has pioneered bridging the medicated and non-medicated gap with line extensions to its famous brands. Recent rollouts include PanaNatural Cough Syrup in UAE, Excedrin Head Care (to support “head health”) in USA, and VoltaNatura (topical analgesic) and FeniNatural (anti-itch) in markets across Europe. The latest launch brings natural options to Panadol, Australia’s No.1 systemic analgesic, by filling the maintenance and prevention gap that remains largely unaddressed within the category.
Meanwhile, regulatory changes — discussions by the TGA to reduce paracetamol pack sizes, and the upscheduling of modified-release paracetamol in 2020 — make diversification an attractive option locally. These are important developments for Haleon in Australia, the analgesics category and the global consumer healthcare market. In fact, natural, organic and even vegan products are at the cutting edge of our industry.
The CHC industry is truly at a crossroads, with a great deal of uncertainty expected in the years ahead. That uncertainty extends to regulatory, and industry associations around the world keep a watchful eye open to make sure that our best interests are defended at a time when regulators want to erect even higher barriers to prevent side-effects, and in doing so discourage innovation. In that context, I’d like to give a shout-out to the work of the Global Self-Care Federation and its new Chair, Manoj Raghunandanan, and Director-General Judy Stenmark. Here at Nicholas Hall Group, we are highly supportive of the work of GSCF and for several years have sponsored their two interns. Keep up the good work!
Now is your last chance to save up to GB£1,350 when you pre-order the 2023 edition of our Innovation in CHC report, publishing this week! Drawn from CHC New Products Tracker, this report explores the rise of naturals and innovation by marketer, region and country. It showcases 10 major ingredient trends, 5 delivery format trends and 100 key innovations from 2022. For more information, or to pre-order your copy with the pre-publication discount, contact melissa.lee@NicholasHall.com.